

Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab.

[Koutras AK](#), [Antonacopoulou AG](#), [Eleftheraki AG](#), [Dimitrakopoulos FI](#), [Koumarianou A](#), [Varthalitis I](#), [Fostira F](#), [Sgouros J](#), [Briasoulis E](#), [Bournakis E](#), [Bafaloukos D](#), [Bompolaki I](#), [Galani E](#), [Kalogeras KT](#), [Pectasides D](#), [Fountzilas G](#), [Kalofonos HP](#).

Source

Department of Medicine, Division of Oncology, University Hospital of Patras, Rion, Greece.

Abstract

The aim of the study was to evaluate the association of vascular endothelial growth factor (VEGF) genotypes with treatment efficacy in a randomized trial. This study compared two chemotherapy regimens (FOLFIRI versus XELIRI) combined with bevacizumab, as first-line treatment for metastatic colorectal cancer. DNA was extracted from blood samples of 173 patients participating in the trial. Genotyping was performed for selected SNPs (VEGF-1154, +936, -634, -2578 and -1498). All candidate genotypes were evaluated for associations with overall survival (OS), progression-free survival (PFS) and response rate (RR). There were no significant differences with respect to the distribution of genotypes in the treatment groups. The VEGF-1154 GG genotype was more frequent in patients not responding to treatment compared with responders (65.5 versus 39.8%, $P=0.032$). Furthermore, the VEGF-1154 GG genotype was associated with inferior median OS compared with GA (hazards ratio=1.68; 95% confidence interval: 1.10-2.57; $P=0.016$) or with the alternative genotypes (GA and AA) combined (hazards ratio=1.62; 95% confidence interval: 1.09-2.40; $P=0.017$). In multivariate analysis, the VEGF-1154 GG genotype remained a significant adverse factor for OS. Our results support the potential predictive ability of VEGF genotypes in patients with metastatic colorectal cancer receiving irinotecan-based chemotherapy plus bevacizumab, in terms of RR and OS. However, current results should be validated prospectively, in larger cohorts. The Pharmacogenomics Journal advance online publication, 16 August 2011; doi:10.1038/tpj.2011.37.